REVIVEPEPTIDES
0

The marker that confirmed the mechanism and raised the one theoretical concern, as the trials measured it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
In the phase 3 trials IGF-1 rose by roughly a hundred nanograms per millilitre on average in the tesamorelin groups and was unchanged with placebo, confirming that the drug increased growth hormone secretion. Most participants remained within the age-adjusted normal range; around a tenth to a fifth exceeded the upper limit at some point, and the protocols reduced exposure or withdrew participants whose IGF-1 rose far above it. The label notes the increase, advises monitoring, and states that the long-term consequences of raised IGF-1 are unknown, citing the epidemiological association between IGF-1 and some cancers. The rise plateaued over weeks, as feedback would predict.

What was measured

IGF-1 at baseline and at intervals through 52 weeks, by standardised immunoassay with age- and sex-adjusted ranges. The mean rise was prompt and then flat. The proportion above range was reported and was higher in the continued-treatment groups at 52 weeks than at 26. IGF-1 fell to baseline in participants switched to placebo.

IGFBP-3 and growth hormone itself were measured in substudies and moved as expected.

Why the rise is bounded

Because the released growth hormone feeds back on the pituitary and hypothalamus, the response to a releasing-hormone analogue reaches a plateau that administered growth hormone does not. The proportion of participants exceeding the range reflects individual variation in pituitary reserve and liver sensitivity rather than an unbounded effect. This is the pharmacological argument for the class and the trials bore it out.

The IGF-1 standard and the assay harmonisation issues on this site apply to these measurements.

The concern and its status

Higher circulating IGF-1 associates with some cancers in cohort studies, as the IGF-1 pages describe. No excess of cancer was seen in the tesamorelin trials, which were too short and too small to detect one. The label states the uncertainty. This page states it too, and describes no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What was measured?

IGF-1 at baseline and at intervals through 52 weeks, by standardised immunoassay with age- and sex-adjusted ranges. The mean rise was prompt and then flat. The proportion above range was reported and was higher in the continued-treatment groups at 52 weeks than at 26. IGF-1 fell to baseline in participants switched to placebo.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

→ Tesamorelin Pack — 20 mg → Circulating IGF-1 and cancer risk → Tesamorelin and IGF-1 monitoring

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.